Marksans Pharma Limited (NSEI: MARKSANS)
Health Care · Pharmaceuticals · IN
Rs321.30
-3.51% today · +80.7% 1Y
Marksans Pharma Limited (NSEI: MARKSANS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.52B and employs 1,685 people.
Over the last twelve months the share price has gained 80.7%, trading between 155.00 and 345.50.
Tweenvest scores Marksans Pharma Limited across four factors: quality 79/100, value 20/100, growth 69/100, dividend 71/100. Its strongest factor is quality.
MARKSANS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.52B
- Revenue (TTM)
- $335.45M
- P/E
- 28.19
- EPS
- 11.40
- Dividend yield
- 0.28%
- Beta (5Y)
- 1.12
- 52-week high
- Rs345.50
- 52-week low
- Rs155.00
- Avg volume (3M)
- —
- Shares outstanding
- 453.16M
- Employees
- 1,685
- Next earnings
- —
About Marksans Pharma Limited
Marksans Pharma Limited, along with its subsidiaries, operates internationally, engaging in the full spectrum of generic pharmaceutical formulation activities, from research and development and manufacturing to marketing, distribution, and sales. The company's extensive product portfolio addresses a wide array of medical needs across numerous therapeutic categories. These include pain management (analgesics), conditions such as benign prostatic hyperplasia and various forms of diabetes, neurological disorders like epilepsy, anti-inflammatory conditions, hyperparathyroidism, and gastrointestinal issues like those requiring antacids or treatments for gastroenterology. Marksans Pharma also develops solutions for cardiovascular health, hormonal imbalances, oncology, gynecology, and hypertension, alongside producing antibiotics, antifungals, antiulceratives, vitamins, dermatological preparations, cephalosporins, injectables, anti-allergy, and antibacterial medications. Furthermore, the firm offers contract research and manufacturing services. Established in 1992, its corporate headquarters are situated in Mumbai, India.
- ISIN
- INE750C01026
- Founded
- 1992
- Listed since
- Jul 19, 2002
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.